INNO-GENE SA ZY -10 (WQ3) — Capital Reinvestment Ratio

Latest as of June 2025: 12.04x

INNO-GENE SA ZY -10 (WQ3) has a Capital Reinvestment Ratio of 12.04x as of June 2025, meaning it reinvests 12% of its operating cash flow (€54.00K) in capital expenditures (€650.00K). See WQ3 equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

12.04x
Capex / Operating Cash Flow

Operating Cash Flow

€54.00K
EUR

Capital Expenditures

€650.00K
EUR

Data as of

Jun 2025
Most recent filing

INNO-GENE SA ZY -10 Capital Reinvestment Ratio (2021–2021)

This chart tracks INNO-GENE SA ZY -10's Capital Reinvestment Ratio across 1 annual periods. Check INNO-GENE SA ZY -10 total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for INNO-GENE SA ZY -10 (2021–2021)

Year-by-year Capital Reinvestment Ratio for INNO-GENE SA ZY -10 from 2021 to 2021. For live market cap and broader valuation context, see WQ3 market cap.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2021 0.01x €6.75 Million €82.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow